Researchers are developing an mRNA vaccine to protect against Clostridioides difficile bacteria, known for causing severe ...

Clostridioides difficile is a notoriously nasty intestinal bug ... as vaccinated mice challenged with a second C. difficile infection after six months fared about as well as they did in the ...

C. diff infection is often associated with the use of broad-spectrum antibiotics, which disturb the equilibrium of the microbial colonies living in the colon. This disruption allows an overgrowth of ...

This leaves them open to bacterial infections such as C. difficile, which infects the gut and releases toxins that cause a variety of ailments including diarrhea, severe cramping and in some cases ...

Initially used to combat recurring Clostridium difficile (C. diff) infections, FMT boasts a success ... treatment for conditions like inflammatory bowel disease (IBD), irritable bowel syndrome ...

C. perfringens is a widespread bacterium found ... It produces over 20 toxins, with the β-2 toxin (CPB2) being linked to intestinal infections. CPB2, first identified in piglets with necrotizing ...

XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...

intestinal infections, or other GI disorders, Field says. Being physically active is crucial for gut health, especially for those who are constipated, says Dr. Reezwana Chowdhury, a ...

Constipation, urine infections, throat, chest or bowel infections, viruses, inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), diabetes and abdominal migraine are just ...

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies with an initial focus on gastrointestinal diseases, today announced the oral presentation of ...